Clinical Significance of Preoperative Serum CEA and CA 19-9 Level in Different Stages of Gastric Cancer

Abstract

The aim of this prospective study was to identify any relationship of CEA, CA 19-9 with different stages of carcinoma stomach. The current study was conducted at the Department of General Surgery, Bangabandhu Sheikh Mujib Medical University, Bangladesh from January 2021 to February 2022. In this cross-sectional observational study, 52 patients with histologically established stomach cancer were enrolled. Patient was categorized into two groups (elevated /not elevated CEA and CA19-9 group) after preoperative measurement of CEA and CA19-9 level. About 65.4% of cancers are stage III, 23.1% are stage IV, but stage I tumors account for only 1.9% of all malignancies. In stage I, II, III, IV stomach cancer, CEA increased by 4.3%, 13%, 60.9%, 21.7% and CA19-9 increased by 0.0%, 21.1%, 63.2%, 15.8%. Gastric cancer with raised serum CEA and CA 19-9 level may present as advanced stage. Any extensive surgery in this stage may produce poorer outcome. In GC, CA 19-9 and CEA may be used as monitoring and prognostic tool.